ADAM BLANTON: Open Payments
NPI 1760142699 · GIBRALTAR, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,865 in 103 payments from 15 companies in 2025. Trend: 2023 $666 · 2024 $1,459 · 2025 $1,865
Food & beverage: $1,857Education: $8
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $360 |
| Vanda Pharmaceuticals Inc. | 14 | $280 |
| Otsuka America Pharmaceutical, Inc. | 14 | $272 |
| Lundbeck LLC | 12 | $212 |
| ABBVIE INC. | 11 | $188 |
| Supernus Pharmaceuticals, Inc. | 16 | $154 |
| Axsome Therapeutics, Inc. | 4 | $88 |
| Alkermes, Inc. | 4 | $73 |
| Neurocrine BioSciences, Inc. | 2 | $63 |
| Collegium Pharmaceutical, Inc. | 2 | $41 |
Products named: REXULTI, CAPLYTA, HETLIOZ, VRAYLAR, Qelbree, ABILIFY MAINTENA, Auvelity, ARISTADA.
Industry payments across MI — which companies pay providers there.
